AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2020

Jun 1, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2020-05-28

Reporting Person: Schenkein David P (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-28	Stock options (right to buy)	$53.35	A	8096	Acquired	2030-05-28	Common stock (8096.0)	Direct
2020-05-28	Restricted stock units	$	A	1686	Acquired		Common stock (1686.0)	Direct

Footnotes

F1: This option was granted on May 28, 2020. This option vests as to 100% of the underlying shares on May 28, 2021.

F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested.